Political Commentary & Public Opinion - The report highlights a perceived failure of Donald Trump to quell the Epstein story, leading to a revolt among MAGA pundits and influencers [1] - It notes the growing MAGA anger and demand for the release of the Epstein client list, suggesting this is a key motivating issue for Trump's base [1] - The analysis points out a shift in Fox News' coverage, downplaying the Epstein controversy in favor of other topics [1] - The report suggests Trump's base may feel betrayed if they perceive a cover-up related to the Epstein case [1] Transparency & Accountability - The report criticizes the lack of transparency from the Trump administration regarding the Epstein files [2][3] - It mentions accusations that the administration is behaving like the "deep state" by refusing to be transparent [2][3] - The report references Trump's past vows to declassify the Epstein files and questions his current reluctance [2] Cognitive Dissonance & Conspiracy Theories - The analysis discusses how Trump's followers manage cognitive dissonance regarding his personal behavior by embracing conspiracy theories about sex trafficking and a "deep state" [3] - It suggests that some followers may be avoiding the idea that Trump is protecting himself in the Epstein case [3][4]

There's a psychology to this and we we don't want to do the thing of taking millions of people and saying they all have the same motivation, but political scientists study this um paranoid style in American politics. Um pre-in um emphasis on the political potency of conspiracy theories, particularly when they dovetail with a wider kind of extreme rabbit or messianic view of things. The problem for a lot of Trump followers is they've had to spend a lot of time minimizing everything from him saying on tape th ...

Public blockchains offer decentralization and transparency. Private chains offer control and speed.Each model has trade-offs.The key is understanding what security really means for your use case and how to evaluate the risks. ...

Breaking news. The Republican controlled House Rules Committee has just voted to block the release of the Epstein files. Joining us now, the member of Congress who forced that vote, Democratic Congressman Roana of California.Congressman Connor, give us the latest uh situation with the House Rules Committee. Well, it's very disappointing. I had a very simple amendment that the full Epstein files should be released.It went for a vote to the House rules committee. Jim McGovern, who is the ranking member for Ho ...

RT Troy 🟪 (@troyharris__)Today is my first day at @blockworksres.I joined the data team to help build out industry leading dashboards on your favorite projects. For crypto to change the world, it needs to be trusted by the world. Follow along as I do my part to make crypto more transparent.🟪/acc ...

Opioid Crisis & Regulatory Reform - FDA 承认在阿片类药物监管方面存在失败，并对由此造成的阿片类药物滥用危机表示担忧 [1] - FDA 计划审查 OxyContin 等药物的标签，确保其准确性并与科学依据相符 [2] - FDA 致力于移除咨询委员会中所有可能的行业成员，以维护科学流程的公正性 [3] - FDA 将加强对已批准药物的上市后监测，利用大数据识别潜在的安全信号 [3][4] - FDA 将取消阻止安全流行病学研究的权限，确保安全团队能够自由工作，避免利益冲突 [5] Drug Approval & Transparency - FDA 正在进行全国范围的意见征集，听取 CEO 们对改进 FDA 的想法 [13] - FDA 致力于提高透明度，公开决策信函，使药品开发商能够了解药品未被批准的原因 [14][17] - FDA 正在利用 AI 技术来组织和分析大量的申请文件，以实现现代化 [18] - FDA 推出了一项试点计划，对于符合美国国家优先事项的药物，提供优先审查凭证，将决策时间缩短至 1-2 个月 [20] - FDA 员工数量自 2007 年以来翻了一番，存在大量冗余，需要进行整合 [21] Investment & Deregulation - FDA 采取放松监管的态度，旨在加快审批流程，同时不降低安全标准 [23] - FDA 将与行业保持沟通，确定哪些产品符合国家优先事项，例如满足未满足的公共卫生需求、实现国内生产以及提高药品的可负担性 [24] - FDA 计划对承诺在 OECD 国家和美国之间实现药品价格均等化的公司发放国家优先审查凭证，以激励市场中的良好行为 [25]

Today, multiple Democratic lawmakers, including some from Texas, are formally demanding answers from the administration about the impact of budget cuts and DHS policies on the government's ability to respond to the devastating floods. Texas Democratic Congressman Greg Quesar is one of them, chair of the Congressional Progressive Caucus, and he joins me now. Congressman, it's good to have you on the program again.What are the specific concerns both that you've heard raised but also the questions you want ans ...

Government Transparency & Whistleblower Protection - The report highlights concerns about the Trump administration's efforts to discredit whistleblowers and suppress information sharing with the press and public [1] - The analysis points out the importance of public servants speaking out to reveal information about the administration's actions [3] - The report mentions the Trump administration's use of polygraph tests to identify leaks and screen employees for loyalty at the FBI [7][8] - The analysis notes the firing of 18 inspectors general across the government, who are critical to protecting whistleblowers [8][9] - The report raises concerns about Trump's nomination of Paul Andracia to lead the Office of Special Counsel, an office that protects whistleblowers [10] Personnel & Qualifications - The report emphasizes Paul Andracia's limited government experience (barely a year) and questions his qualifications to run the 110-person Office of Special Counsel [11][12] - The report highlights Andracia's past association with controversial figures like Andrew Tate and his activity on social media, raising concerns about his judgment and objectivity [12][13][14] Political Implications - The report suggests that the appointment of Andracia is a deliberate attempt to undermine protections for federal employees who speak out against the administration [15] - The report mentions that Andracia's nomination requires Senate confirmation, leaving a sliver of hope for closer scrutiny [16]

Are we born as good communicators or do simple words still have an impact. On Mother's Day, I was telling my wife, Grace, a university instructor, how it was obvious that our four-year-old son, Rai, feels comfortable speaking in front of an audience at his school ceremony. I thought that given what we do in life, he kind of enjoys using a microphone in public.However, she reminded me how both of us were completely different not so long ago. And this got me thinking about my sophomore year when a group of st ...

Drug developers and inventors of new drugs are trying to figure out how do they get through this long, gnarly regulatory process. Well, we can be more transparent. We can provide better communications. We can provide guidance. We can answer questions on demand.And we are announcing that we're going to make our decision letters public so that drug developers can see why drugs are not accepted at the FDA. Why weren't they public. Some of the drug companies don't want them public.We learned that most companies ...